Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

November 14, 2023

NASDAQ US Health Care Biotechnology earnings 31 min

Earnings Call Speaker Segments

Jeff Cohn

executive
#1

Thanks, operator, and good afternoon to all of you. We appreciate you being on this Heron Therapeutics call today to go over the financial results for the third quarter, which closed on September 30, 2023. Joining me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; and Ryan Craig, Vice President of Marketing. If you're on the conference call, slides are available through the webcast, and you'll also be able to find them on the investor relations page of our website once today's call wraps up. Before we get started, a quick reminder that the company will be making forward-looking statements during this call. Please note that anything that isn't a statement of historical fact counts as a forward-looking statement. That covers comments regarding the company's projections, expectations, plans, beliefs, and future performance, and all of these are forward-looking statements under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Such statements rely on judgment and analysis as of today, and they carry numerous significant risks and uncertainties that might cause actual results to differ materially from what those forward-looking statements describe. The risks and uncertainties tied to the forward-looking statements in this call and webcast are laid out in the Safe Harbor statement in today's press release as well as in Heron's public periodic filings with the SEC. Unless the law requires it, Heron takes on no obligation to update these forward-looking statements for future events or actual outcomes, and it has no intention of doing so. With that, I'd like to hand the call over to Craig Collard, Chief Executive Officer.

Craig Collard

executive
#2

Appreciate that, Jeff. Good afternoon, everyone, and thanks for joining us on the call today to discuss Heron Therapeutics' results for the third quarter of 2023. We're happy to share updates on the strategic moves we've made lately, how we performed financially during Q3, what we expect for the remainder of 2023, and our outlook covering all of 2024. It's been roughly six months since I came aboard as Heron's CEO, and during that stretch we've made meaningful progress toward getting the business to the proper size so it lines up with where we're headed strategically. We've rolled out a thorough effort to streamline how our finances operate, which has boosted both efficiency and accountability throughout the company. Because we're dedicated to running things at a high standard, we've managed to merge several commercial teams, remove duplicate efforts, and make our overall organizational structure as effective as possible. Bringing things together this way doesn't just make us more efficient — it also puts us in a better spot to react to what's happening in the market. And finally, we're happy to report that we've put together a fresh strategic vision, one that lays out our objectives and the main moves we'll make. That vision works as a plan for where we're headed, steering what we do so we can grow in a lasting way and give shareholders the most value possible. In the brief period we've been at Heron, what we've done has added up to a lot. Our leadership group is set, and Heron is being reshaped into a company that turns a profit; leaving out stock comp along with depreciation and amortization, we brought operating costs down to $135 million for 2023, compared with $182 million only a year earlier. We expect spending to drop even more, which will bring operating expenses for 2024 to somewhere between $108 million and $116 million. Gross margin is getting better too—it's going from 41% in 2023 up to 62% in 2024, and we think it will level out above 75% starting in 2025 and continuing after that. Several things drove this gross margin shift: fully realizing the benefits of scaling toward bigger batch sizes, talks with the partners who manufacture for us, gains in operational efficiency, and the fact that we no longer have product write-offs tied to ZYNRELEF now that the inventory has expired. Thanks to the money we brought in during the summer, along with the more than $65 million in cash we expect to be holding when the year closes, plus the cuts we've made to spending, we're now in a position to show investors how we get to positive EBITDA by Q4 2024. Under the plan we're working from today, we don't see any need to go out and raise more capital anytime soon. Finally, now that we've built operational efficiency into the business and set our plan out internally, the effect is starting to show up in our product sales. Across the past eight weeks, unit sales for both ZYNRELEF and APONVIE reached record highs. We think that this forward motion is going to keep going as we get nearer to the label expansion we're expecting, the VAN launch, and finally the prefilled syringe — all of which are meeting their development schedules. Now on to how our products performed. The oncology care franchise remains a dependable source of revenue for Heron, bringing in $26.7 million of net sales during the quarter and $79.9 million of net sales so far this year. CINVANTI's net product sales for the quarter reached $23.3 million, up from $21.2 million in the same period of 2022. SUSTOL's net product sales were $3.4 million, an increase from $2.7 million in the comparable period of 2022. Our acute care franchise keeps expanding, posting $4.7 million in net sales during the quarter, along with $12.9 million in net sales on a year-to-date basis. Our new strategic plan is now firmly in place, and we're eager to watch these initiatives take hold and fuel ongoing growth across our product lineup. For the quarter, APONVIE recorded net product sales of $350,000. ZYNRELEF's net product sales for the quarter reached $4.4 million, versus $2.7 million in the same period of 2022. At this point I'll hand things over to Ryan Craig, who leads our Marketing team, so he can walk you through a quick overview of our commercial strategy. Over to you, Ryan.

Ryan Craig

executive
#3

Thanks, Craig. Our strategic plan is now locked in, and we're eager to watch it take shape and expand the acute care franchise. The sales force we have is outstanding, and the commercial organization has never been more tightly aligned. When it comes to acute care, the aim is to own the perioperative space, since APONVIE and ZYNRELEF together deliver a best-in-class one-two punch backed by our clinical profile; we're out there promoting innovative solutions for two of the heaviest burdens tied to surgical procedures: post-op nausea and vomiting, and pain. With APONVIE, we're starting with above-the-waist surgical procedures; those procedures — bariatric, ENT, neurological, and plastics, for instance — carry a greater sensitivity to post-op nausea and vomiting, since PONV can lead to serious issues when it isn't handled properly. What we've seen early on with APONVIE suggests this is a sensible, receptive place to begin getting on formulary, and we've shown we can extend past that starting point into other surgical lines. Beyond our clinical profile, the 2020 PONV guidelines further call for three distinct agents working through separate pathways, which backs adding APONVIE into protocols. With ZYNRELEF, our commercial execution spanned widely and reached many specialties with differing chances of success. Given our growth, the business base we have now, and the opportunity ahead, we've settled on orthopedic surgeries as the main focus. Going forward, our execution will line up much more closely with that customer base, for a number of reasons. First, the worst pain patients may feel tends to come with orthopedic procedures rather than some of the other indications. On top of that, orthopedic surgeons generally perform a greater volume of procedures, which would encompass the anticipated spine and shoulder indications if the FDA grants sNDA approval on January 23rd. Zeroing in on orthopedic surgeries also opens the door to working with distributor representatives, something we've piloted in the field with terrific results. APONVIE launched in March of this year, and we keep building traction in our targeted institutions. We're still identifying advocate specialists who want to tackle the burden of PONV and improve how it's treated. Right now, we have 66 P&T reviews requested by targeted customers, 10 P&T reviews scheduled and confirmed with a date, and nine new P&T approvals in the month of October by itself. Requesting P&T, confirming a date, and finally securing approval can take four to six months in certain cases. That's where our focus sits today — building a broad opportunity base that will produce consistent ordering at rising volumes. So far, 156 accounts have completed this process and gone on to order APONVIE. Out of those 156 new accounts, we've picked a handful as examples that show encouraging signs of growth. What began as first orders across those four accounts has grown into repeat ordering at higher and higher volume levels. Those accounts followed through on the strategy we laid out before, beginning with a single surgical line, such as bariatric surgery, observing encouraging outcomes, sharing those outcomes through their own networks with other surgical lines, and from there adoption widens. Our own strategic roadmap matches this demonstrated pattern, along with other scenarios, and we're eager about what lies ahead as more people become aware. With ZYNRELEF's latest trends, momentum keeps building. Results are starting to show from our sharper concentration on orthopedic procedures — our newest data week, which closed on November 10, marked record highs in normalized units. On top of that, volume for the current eight weeks compared with the preceding eight weeks reflects growth of 16%. This recent trajectory encourages us, and we have every expectation it will persist as we keep carrying out our strategy through the fourth quarter and afterward. Beyond these recent trends, meaningful chances exist to grow ZYNRELEF adoption via near-term regulatory and development milestones. The first is the sNDA PDUFA date, set for January 23rd, 2024; we look forward to a favorable FDA response and are thrilled to bring ZYNRELEF to more patients who could benefit from the added indications. If approved, the opportunity would grow from roughly 7 million procedures covered under our present label to almost 13 million procedures. Second, the vial access needle is presently being developed, with launch targeted for September 2024; this enhancement will cut withdrawal time from more than one minute down to 20 to 30 seconds. According to market research run in Q3, together with feedback we're hearing from customers now, this enhancement matters a great deal and will drive greater utilization. Finally, the prefilled syringe is under development and will prove the most significant advance in how ZYNRELEF is prepared and administered. It removes any time spent in the OR on withdrawal or preparation entirely, since with this product in hand ZYNRELEF would be ready to apply right away. I'll now hand things over to Ira Duarte, our Chief Financial Officer.

Ira Duarte

executive
#4

Thanks, Ryan. Since Craig already covered product performance in his section, I'll just add a few supplemental points about what Q3 2023 looked like for us. For the quarter, product gross profit was $13.2 million, and for the nine months ended September 30th, 2023, it was $37.6 million — representing 42% and 41% of net revenue, respectively. Margins over those nine months ending September 30th, 2023 were pressured by ZYNRELEF inventory write-offs; looking ahead, we anticipate no material ZYNRELEF write-offs. SG&A for the three and nine months ended September 30, 2023 was $24.6 million and $93 million, respectively, compared with $28.2 million and $93.3 million in the same period of 2022. R&D expenses were $13.6 million and $44.9 million for the three and nine months ended September 30, 2023, versus $25.5 million and $96.4 million in the comparable period of 2022. The decrease largely stemmed from lower ZYNRELEF-related costs, as manufacturing scale-up, validation work, and raw material qualifications were completed in 2022; in addition, personnel and related costs declined overall due to the reductions in force implemented in June 2022 and June 2023. We believe further cost reductions in this area are achievable going forward as efficiency keeps improving. Net loss was $25 million in Q3 2023, and $41.9 million in the comparable period of 2022. As for total year-to-date net loss, 2023 stands at $99.8 million, compared with $162.2 million in the comparable period of 2022. I'd like to give a bit more clarity now on what Craig discussed earlier and take you through the last three quarters and the actions we've taken to reduce our overall operational spend and cash burn; we began implementing our corporate restructuring plan in early June, which included multiple cost-saving measures, among them a reduction in force plus company-wide spend reduction overall. We now have much better visibility into our operational spend and can see a clear route to profitability. Looking at the slide from left to right, you'll see our overall operational spend in Q1 2023 was roughly $46 million, which we reduced to $41 million after excluding the highlighted reorganization charges of $13 million. We brought these spends down further to $34 million in Q3 2023 after excluding the highlighted reorganization charges of $4.1 million. On the slide you can see that our operational loss, after excluding stock compensation and depreciation and amortization along with the previously mentioned one-time charges, our overall operating cash burn declined from $90 million in Q1 2023 to $7.2 million in Q2 2023, and $6 million in Q3 2023. Our 2023 operating spend, excluding stock compensation, depreciation and amortization, and the $17.1 million in reorganization costs, will land around $180 million. Also worth noting, our cash and cash equivalents totaled $152.2 million. We figure that, looking ahead, the ongoing operating run rate—after taking out stock comp as well as depreciation and amortization—will come in at roughly $108 million to $160 million, and because we've kept our spending level while revenue continues to rise every quarter, the cash we burn ought to decline from one quarter to the next. Now let's move on to what we anticipate for the rest of 2023 and into 2024. On the slide's left-hand portion, our projected numbers for Q4 2023 are shown, and they reflect net revenues between $30 million and $32 million, along with EBITDA excluding stock compensation that ranges from a $10 million loss to a $6 million loss. As 2023 wraps up, we anticipate keeping a cash and cash equivalent balance of no less than $65 million. When it comes to 2024, our revenue guidance is $138 million-$158 million, and gross margins should improve to a range of 68%-70%. Operating spend, if you set aside stock compensation along with depreciation and amortization, ought to land between $108 million-$160 million, whereas EBITDA excluding stock compensation is expected to range from a $22 million loss to $3 million of income. I want to stress again that we expect to hit positive EBITDA in Q4 2024, and with that outlook, plus our strong balance sheet and the operational plan we're carrying out right now, we don't see any requirement to raise additional capital—a figure like $152.2 million is not something we need to pursue. Craig, I'll hand it back to you.

Craig Collard

executive
#5

Turning to the main takeaways from today's call, you can likely hear how much more assured we sound regarding this business. ...The direction we've set for the company is firm, and the team we have is now delivering against the balance sheet to reach profitability, and we don't anticipate needing to raise additional capital. On the road toward profitability, our operating expenses, gross margin, and EBITDA are each trending favorably. The oncology franchise keeps exceeding expectations, so for 2023 we are lifting guidance from $99 million to $103 million up to a range of $104 million-$106 million. Momentum behind our acute products is also powerful, since ZYNRELEF and APONVIE have each posted record unit volume across the last eight weeks. Finally, we have a label expansion plus the VAN launching for ZYNRELEF, and both ought to serve as meaningful growth drivers for that product. At this point I'd like to open the line for questions.

Carl Byrnes

analyst
#6

Excellent. Nice work on the momentum, and I appreciate taking the question. To start, on gross profit margin for Q3, backing out the inventory write-offs, that comes to 66%, as I remember from the release. Your Q4 guidance appears to be 62%, and for full-year 2024 it's 68%-70%. I'm curious whether mix is a factor, what distinguishes Q3 from Q4 at that 62%, and how should we think about gross profit margin unfolding past 2024 — is there a ceiling, some gross profit objective or margin objective?

Craig Collard

executive
#7

Yes, Carl, I appreciate that. Once more, regarding our gross margin, consider APONVIE initially — it'll carry the biggest effect simply due to overall revenue; right now we produce that item at a pair of separate contract manufacturers. Through 2022, and really up to the beginning of 2023, we were still completing scale-up work and similar efforts, moving from a batch of 400 kg up to 1,000 kg. That meant you had a pricing blend across those two batch sizes. Past that point, our main manufacturer is Alcami, where a 1,000 kg batch is now running, while our second manufacturer is Curia, handling a secondary operation at 300 kg. So a blend exists in that case too. Once things settle somewhat, that explains why it keeps getting better going forward. And, once more, looking at the later years, you'll see, as I mentioned, an overall gross margin across all products somewhere in the mid-70%s area. ZYNRELEF, again, stays fairly steady, though the write-offs we just had did impact it, so nothing significant is shifting there. The sole additional product that future scale changes and similar matters will touch is APONVIE, and there too we're shifting from a 400 kg batch to one of 1,000 kg, which ought to push those margins to roughly the lower 70%s. So, once more, that's my reasoning for saying that overall we'll land in the mid-70%s to perhaps 80% territory as we go forward.

Carl Byrnes

analyst
#8

Great, that's a big help. And as a quick follow-up — obviously, you know, you could turn a profit tomorrow if the only thing you cared about was the CINVANTI franchise. But it's clear the expansion comes from acute care, from APONVIE and ZYNRELEF. So I'd like to hear your thinking on what peak sales could look like for ZYNRELEF and APONVIE, and how that ramp might unfold over time, based on your own internal work. Thanks.

Craig Collard

executive
#9

Yeah, it's a good question, because from an investor's perspective, I'd say the oncology piece of the business functions almost like a hedge — it safeguards your investment, in a sense. What I mean by that, and I think this is what you're getting at, is that if profitability were the only goal, we could be a plain oncology company tomorrow and hit positive EBITDA before the week is out. But that isn't where we're headed. We believe the opportunity here is far larger. The actual growth story sits with the two products capable of dominating perioperative care, and those are APONVIE and ZYNRELEF, which we believe can each be multi-hundred million products. Just consider the market size, and again, we're encouraged by what we're doing right now — particularly with ZYNRELEF, with the VAN, the expanded label, and eventually the prefilled syringe. So it will take some time to reach that point, but there's a genuine growth story on the acute side of the business. And the beauty of it is that you have a base of business throwing off capital that keeps getting more profitable.

Carl Byrnes

analyst
#10

Excellent. I really appreciate it. And once more, well done on the advances.

Craig Collard

executive
#11

Thank you, Carl.

Nick Lorusso

analyst
#12

Thanks a lot. Nick here, filling in for Boris. I've just got a few questions about ZYNRELEF. To start, given how slowly ZYNRELEF has grown so far, what exactly is behind that 48% year-over-year gain in the acute care franchise? And related to that, is it mostly because of the VAN and the sNDA? How soon do you expect those two to make an impact? Specifically, how fast will the VAN get distributed? How fast will physicians adopt the new procedures for the sNDA? Thanks.

Craig Collard

executive
#13

Yeah. So once more, we feel quite confident about that 48% growth, particularly given how the product is trending right now. We've implemented several things in the field involving targeting, alignment, and so forth. So then, if you consider the sNDA, which will broaden the indications, and again, I believe, assuming our review date of January 23rd, in the period leading up to it, there's clearly some training and similar work we'll be doing to get ready, so that ought to be felt relatively soon; and then not long after, as you said, you've got the VAN arriving in September. What we intend to do is try to drain the initial kits currently out there, in terms of the inventory with ZYNRELEF, and then introduce that new kit, which is somewhat more of a seamless transition. So that ought to be felt almost right away afterward. And here's why that matters so much, and again, what our market research and the time spent with the reps have taught us, is that case management for this product, because of how the product must be prepped, is truly hard. So if you can make that better, and what the VAN accomplishes is it not only enhances the sterility issue, but it also enhances the pull of the product and simply the mechanism of it; it genuinely simplifies that, and we believe that will greatly assist us with the case management piece, letting our reps spend less time in the OR, sort of handholding through surgeries and reaching more physicians and expanding and growing the product. And so it makes that problem far better. And then in the end, as we progress toward a prefilled syringe, the beauty of the prefilled syringe, and really, it's just this simple, is it removes the device aspect from the drug. So rather than being a device drug type of combination, we become just a drug. If you look at our drug clinically versus other things available on the market, it truly does have a superior play there in terms of the clinical data and what it does and so forth. That's the spot where we receive a great deal of useful input, and that is exactly why our outlook on this is so favorable.

Nick Lorusso

analyst
#14

That's really useful. Then I have one more question. So you said the second sNDA, in January, would bring us to roughly 13 million procedures altogether at that point. Of those, how many are going to be orthopedic procedures?

Ryan Craig

executive
#15

Yes, this is Ryan Craig. So from that extra five to six million procedures, around 70% are going to be ortho. And that's why, when Craig talked about our traction, 60% of the business we have right now on ZYNRELEF is orthopedic procedures too. So once we get approval, which we expect by the end of January, that should give us a seamless point of communication. That's the area where we've done best so far, and it clearly fits with our strategy too.

Nick Lorusso

analyst
#16

Understood. Many thanks.

Craig Collard

executive
#17

I appreciate it. Thanks for asking.

Serge Belanger

analyst
#18

Hello, I'm Serge. There are a few additional questions I'd like to ask regarding ZYNRELEF. My understanding is that the bulk of the orthopedic emphasis involves procedures on knees and hips. I'm interested in who you're up against at this point. Would that be generic bupivacaine, or is it EXPAREL? Also, regarding the label expansion, which other orthopedic operations do you anticipate being able to pursue after January, if approval comes through?

Craig Collard

executive
#19

Yes, I believe your view of the competitive landscape is accurate. What I mean is, generally speaking, it's either generic bupivacaine or EXPAREL. Frequently these days, when EXPAREL is used, it tends to be part of a nerve block approach, which means, as you might expect, an anesthesiologist may be participating. However, what makes this product so appealing is that after it's administered and the clinical data become visible, we truly gain substantial support from orthopedic surgeons; as a result, we've achieved our greatest, honestly our strongest, level of success in that area; and another factor that deserves a mention is that this is the setting where the majority of genuine pain occurrences during surgery happen. As you know, hips and knees are capable of being extraordinarily painful, so once more, we believe our product fits that area extremely well. Oddly enough, although those are indeed the things we compete with, our difficulty has stemmed less from rivals on the clinical side and more from our own preparation of the product; that's the reason I keep emphasizing the VAN and similar matters. Consequently, with the broader label, we anticipate gaining shoulders right away, and that will represent a direct... Any doctor performing orthopedic work could transition straight into shoulders using our products, so that ought to happen immediately; after that, we believe spine will likely follow as a closely connected area, which would involve perhaps a separate group of physicians, yet it falls into a very comparable category in terms of a space where we think we can perform rather effectively.

Serge Belanger

analyst
#20

All right. And when it comes to possible partnerships, would you consider that more of a nice-to-have, or is it something that ranks as a priority moving forward for ZYNRELEF?

Craig Collard

executive
#21

No, it ranks as a priority. Once more, yes, it's, it's a terrific question because, once more, looking back, I realize I sound like a broken record, yet how the product is prepped and all of that means that when you consider drug reps broadly, they typically aren't found in OR suites. That said, the people who are in OR suites, particularly the ortho space suites, are the, you know, medical device reps. They're present at essentially all of these surgeries. So in our case, we've, we've carried this out across a few different territories and found success where we had a — we have a partnership involving a distributor rep. Our perspective is, if we rolled that out nationally and managed to get, you know, say, a group of 500 or 600 representatives who could supplement and be available for case management, that's simply an enormously big win for us, particularly when you consider bringing in the VAN, we ought to build on that regardless. So from our standpoint, it's completely logical. It ranks as a priority.

Serge Belanger

analyst
#22

Alright, thanks a lot. Nice work on the advancement, and I appreciate all the figures you shared this evening.

Craig Collard

executive
#23

Thanks, Serge. We appreciate that.

Craig Collard

executive
#24

Thanks, operator. I want to express appreciation to all of you for being on this call, and your patience truly means a lot to us. We believe we are achieving very significant progress at the company and are genuinely starting to reverse things, and we can't wait for the call covering the next quarter. Thanks.

Operator

operator
#25

Everyone, that brings us to the end of this call. We appreciate you joining us. You're free to hang up now. Farewell.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.